Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 6, 1999, Pages 1577-1581

  Nilsson, Lennart ^a   Takemura, Toshiya ^a   Eriksson, Per ^a   Hamsten, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Endothelial cells; Fibrates; PAI 1; Transcriptional activity

Indexed keywords

BEZAFIBRATE; CLOFIBRIC ACID; FENOFIBRIC ACID; GEMFIBROZIL; MESSENGER RNA; PIRINIXIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RNA ANALYSIS; VASCULAR ENDOTHELIUM;

EID: 0032983734     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.6.1577     Document Type: Article

References (28)

1. Schonfeld G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis. 1994;111:161-174.
2. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
3. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis. 1990; 10:1067-1073.
4. Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb. 1992;12:19-27.
5. Kaneko T, Wada H, Wakita Y, Minamikawa K, Nakase T, Mori Y, Deguchi K, Shirakawa S. Enhanced tissue factor activity and plasminogen activator inhibitor-1 antigen in human umbilical vein endothelial cells incubated with lipoproteins. Blood Coagul Fibrinolysis. 1994;5:385-392.
6. Sironi L, Mussoni L, Prati L, Baldassarre D, Camera M, Banfi C, Tremoli E. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol. 1996;16:89-96.
7. Avellone G, Di Garbo V, Cordova R, Panno AV, Ranelli G, de Simone R. Bompiani GD. Fibrinolytic effect of gemfibrozil versus placebo administration in response to venous occlusion. Fibrinolysis. 1993;7: 416-421.
8. Andersen P, Smith P, Seljeflot I, Brataker S, Arnesen H. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemost. 1990;63:174-177.
9. Keber I, Lavre J, Suc S, Keber D. The decrease of plasminogen activator inhibitor after normalization of triglycerides during treatment with fibrates. Fibrinolysis. 1994;8:57-59.
10. Bröijersen A, Eriksson M, Wiman B, Angelin B, Hjemdahl P. Gemfibrozil treatment of combined hyperlipoproteinemia: no improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. Arterioscler Thromb Vasc Biol. 1996;16:511-516.
11. Kockx M, de Maat MPM, Knipscheer HC, Kastelein JJP, Kluft C, Princen HMG, Kooistra T. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients. Thromb Haemost. 1997;78:1167-1172.
12. Fujii S, Sobel BE. Direct effects of gemfibrozil on the fibrinolytic system: diminution of synthesis of plasminogen activator inhibitor type I. Circulation 1992;85:1888-1893.
13. Arts J, Kockx M, Princen HMG, Kooistra T. Studies on the mechanism of fibrate-inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey. Arterioscler Thromb Vasc Biol. 1997;17:26-32.
14. Nordt TK, Kornas K, Peter K, Fujii S, Sobel BE, Kübler W, Bode C. Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type 1 induced by insulin and its precursors. Circulation. 1997;95: 677-683.
15. Fujii S, Sawa H, Sobel BE. Inhibition of endothelial cell expression of plasminogen activator inhibitor type 1 by gemfibrozil. Thromb Haemost. 1993;70:642-647.
16. Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost. 1994;72:44-53.
17. Alessi MC, Peiretti F, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997;46:860-867.
18. Eriksson P, Reynisdottir S, Lönnqvist F. Stemme V, Hamsten A, Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia. 1998;41:65-71.
19. Edgell C-JS, McDonald CC, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci U S A. 1983;80:3734-3737.
20. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor. NY: Cold Spring Harbor Laboratory; 1989.
21. Eriksson P, Nilsson L, Karpe F, Hamsten A. A very low density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene is implicated in the impaired fibrinolysis in hypertriglyceridemia, Arterioscler Thromb Vasc Biol. 1998;18: 20-26.
22. Auwerx J. Regulation of gene expression by fatty acids and fibric acid derivatives: an integrative role for peroxisome proliferator activated receptors. Horm Res. 1992;38:269-277.
23. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661-1669.
24. Mussoni L, Banfi C, Sironi L, Baldassare D, Tremoli E. Plasminogen activator inhibitor type 1 secretion by HepG2 cells: opposite effects of two fibric acid derivatives. Blood Coagul Fibrinolysis. 1996;7:503-505.
25. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis. 1992;95:105-117.
26. Avellone G, Di Garbo V, Panno AV, Cordova R, Lepore R, Strano A. Changes induced by gemfibrozil in lipidic, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia. Int J Angiol. 1988;7:270-277.
27. Avellone G, Di Carbo V, Cordova R, Ranelli G, De Simone R, Bompiani G. Effect of gemfibrozil treatment on fibrinolysis system in patients with hypertriglyceridemia. Curr Ther Res. 1992;52:338-348.
28. Pazzucconi F, Mannucci L, Mussoni L, Gianfranceschi G, Maderna P, Werba P, Franceschini G, Sirtori CR, Tremoli J. Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridemic patients. Eur J Clin Pharmacol. 1992;43:219-223.